Avicanna Inc. ("
Avicanna" or the
"
Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the development, manufacturing
and commercialization of plant-derived cannabinoid-based products
is pleased to announce that, through its majority owned Colombian
subsidiary, Santa Marta Golden Hemp S.A.S.
(“
SMGH”), it has completed its first commercial
exports of its proprietary genetics in the form of feminized
cannabis seeds to Peru and Argentina.
The characterization, evaluation and production
of these seeds were all completed through Avicanna’s vertical
integration at SMGH over the past 3 years and validate the
company’s leadership in the breeding and stabilization of cannabis
strains in South America. The seeds are a part of Avicanna’s supply
chain business unit branded as Aureus™, which also includes within
its portfolio feminized seeds, full spectrum extracts, distillates,
isolated cannabinoids (CBD, THC, CBG, and other rare cannabinoids),
and bulk formulations.
Peruvian legislation allows for the importation,
distribution, and sale of cannabis, its seeds, its extracts and
derived products, for medical and scientific research purposes.
Current Argentinian legislation allows for the importation,
distribution, and sale of cannabis, its seeds, its extracts and
derived products, for medical and scientific research purposes
related to the treatment of patients with refractory epilepsy under
the Exception Access Regime. Argentinian legislation also allows
for certain government agencies to cultivate cannabis in
collaboration with provincial agencies whom Avicanna is currently
supplying with its genetics.
Lucas Nosiglia, President of Avicanna LATAM
commented: “After several years of R&D developing our breeding
program, we have established a world-renown genetics platform and
established a regulatory pathway for the export of our genetics
into what is now 4 countries. We are thrilled that our pioneering
efforts have enabled us to supply and support our Argentine and
Peruvian partners with their long-term medicinal cannabis
cultivation programs. With this program we are delivering federally
registered genetics that are optimized and standardized for
industrial agronomic performance in both greenhouse and outdoor
cultivation models.”
To the knowledge of the Company, it carries out
its operations in compliance with all applicable laws in the
jurisdictions in which it operates.
About Aureus™
Avicanna’s supply chain business units are based
in Santa Marta, Colombia and are primarily dedicated to providing
consistent source of cannabinoid raw materials for Avicanna’s
current commercial products and pharmaceutical pipeline for the
global marketplace.
Additionally, under the Aureus™ brand,
standardized cannabis extracts and feminized seeds are made
available to cultivation, cosmetic and pharmaceutical partners
around the world. Aureus branded products are cultivated,
extracted, and manufactured by Avicanna’s subsidiaries in Colombia
where they benefit from optimal environmental conditions to produce
cannabinoid active pharmaceutical ingredients economically and
sustainably and include a range of extracts of CBD, THC and rare
cannabinoids such as CBG. Avicanna’s supply chain business also
benefits from federally regulated legislation in Colombia where the
company is well positioned to be a global supplier of the less
competitive psychoactive extracts including CBD and THC crude oil
to meet the growing global demand.
About Avicanna
Avicanna is a commercial stage Canadian
biopharmaceutical company and an established leader in cannabinoid
research, development, and evidence-based products for the global
consumer, medical, and pharmaceutical market segments. Avicanna
conducts its research in Canada including its R&D headquarters
in the Johnson & Johnson Innovation Centre, JLABS @ Toronto,
Canada, located in the MaRS Discovery District, and in
collaboration with leading Canadian academic and medical
institutions. Avicanna has established an industry leading
scientific platform including advanced R&D and clinical
development which has led to the commercialization of over twenty
products across four main market segments:
-
RHO Phyto™: these medical and wellness
products are an advanced line of pharmaceutical-grade cannabis
products containing varying ratios of CBD and THC. The product
portfolio contains a full formulary of products including oral,
sublingual, topical, and transdermal deliveries that have
controlled dosing, enhanced absorption and stability studies
supported by pre-clinical data. These products are developed using
pharmaceutical drug development processes and are supported with
pre-clinical data. The advanced formulary is marketed with
consumer, patient and medical community education and
training.
-
Pura H&W™: these registered, clinically
tested, cosmetic products include a portfolio of functional CBD
consumer derma-cosmetic and topical products.
-
Aureus™: as a part of Avicanna’s vertical
integration based out of Santa Marta, Colombia its supply chain
business units are primarily dedicated to providing consistent
source of cannabinoid raw materials for Avicanna and its global
partner’s food, cosmetic, medical and pharmaceutical needs. Aureus
branded products are cultivated, extracted, and manufactured by
Avicanna’s subsidiaries in Colombia where they benefit from optimal
environmental conditions to produce cannabinoid active
pharmaceutical ingredients economically, organically, and
sustainably and include a range of CBD, THC and rare cannabinoids
such as CBG extracts and standardized seeds. Company is well
positioned to be a global supplier of cannabinoid raw materials
demand and has already successfully exported its products to over
10 countries in 4 continents.
-
Pharmaceutical pipeline: leveraging from the
company’s scientific platform, vertical integration, and real-world
evidence, Avicanna has established a pipeline of indication
specific cannabinoid-based drug candidates that are in various
stages of clinical development and commercialization. Avicanna’s
drug candidates are in pre-clinical stage and are dedicated to
providing solutions for unmet medical needs in the areas of
dermatology, chronic pain and various neurological disorders.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, call 1-647-243-5283, or contact IR representative
Iryna Zheliasko by email at iryna@chfir.com or by phone
at 416-868-1079 x 229.
The Company posts updates through videos from
the official company YouTube
channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains "forward-looking
information" within the meaning of applicable securities laws.
Forward-looking information contained in this press release may be
identified by the use of words such as, "may", "would", "could",
"will", "likely", "expect", "anticipate", "believe, "intend",
"plan", "forecast", "project", "estimate", "outlook" and other
similar expressions, and includes statements with respect to
the Company’s and SMGH’s abilities to continue to produce
seeds, SMGH’s ability to maintain its licenses to produce seeds, or
SMGH’s ability to export seeds to Peru, Argentina, or anywhere
else. Forward-looking information is not a guarantee of future
performance and is based upon a number of estimates and assumptions
of management in light of management's experience and perception of
trends, current conditions and expected developments, as well as
other factors relevant in the circumstances, including assumptions
in respect of current and future market conditions, the current and
future regulatory environment; and the availability of licenses,
approvals and permits. Although the Company believes that the
expectations and assumptions on which such forward looking
information is based are reasonable, undue reliance should not be
placed on the forward looking information because the Company can
give no assurance that they will prove to be correct. Actual
results and developments may differ materially from those
contemplated by these statements. Forward-looking information is
subject to a variety of risks and uncertainties that could cause
actual events or results to differ materially from those projected
in the forward-looking information. Such risks and uncertainties
include, but are not limited to current and future market
conditions, including the market price of the common shares of the
Company, and the risk factors set out in the Company's annual
information form dated September 3, 2021 and final short form
prospectus dated November 27, 2020, filed with the Canadian
securities regulators and available under the Company's profile on
SEDAR at www.sedar.com. The statements in this press release are
made as of the date of this release. The Company disclaims any
intent or obligation to update any forward-looking information,
whether as a result of new information, future events or results or
otherwise, other than as required by applicable securities
laws.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/40ce1f85-880a-4116-a31b-743009d54eb2
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024